CME: Recurrent and metastatic endometrial cancer: therapeutic updates and optimizing treatment

Details

Endometrial cancer, a type of cancer that originates in the lining of the uterus, is the most common gynecologic cancer and the fourth most common cancer in women living in the United States. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and the most common risk factors are obesity, diabetes, hypertension, and increasing age. Levels of the two hormone estrogen and progesterone fluctuate during the menstrual cycle, resulting in cell proliferation and differentiation that may lead to abnormalities that contribute to malignancies later in life. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis.

By the end of the session the participant will be able to:

• Review guideline-recommended therapy for advanced and recurrent endometrial cancer
• Distinguish between the different forms of therapy presently approved for advanced or recurrent endometrial cancer and apply them to practice
• Describe investigational therapies for advanced or recurrent endometrial cancer and their anticipated place in therapy
• Describe the challenges and barriers to care associated with treating patients with advanced or recurrent endometrial cancer

Target Audience:

The following HCPs: medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with recurrent or advanced endometrial cancer.